Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Malignant neoplasm progression? 88 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 88 reports of Malignant neoplasm progression have been filed in association with INFLIXIMAB (Renflexis). This represents 0.1% of all adverse event reports for INFLIXIMAB.

88
Reports of Malignant neoplasm progression with INFLIXIMAB
0.1%
of all INFLIXIMAB reports
34
Deaths
23
Hospitalizations

How Dangerous Is Malignant neoplasm progression From INFLIXIMAB?

Of the 88 reports, 34 (38.6%) resulted in death, 23 (26.1%) required hospitalization, and 9 (10.2%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 88 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which INFLIXIMAB Alternatives Have Lower Malignant neoplasm progression Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression INFLIXIMAB Demographics